블로그
- Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in ... Hence, this study aims to identify factors predicting sensitivity to HER2 ADC in metastatic breast cancer with metastatic breast cancer and perfor.......
- Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor All women with metastatic breast cancer initiating first-line t.......
- RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ ... inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer However, resistance to this treatment and disease progression remains a major clinical challenge.
- Predictors of receipt of guideline-concordant chemotherapy among ovarian cancer patients in ... Permanente Research on Ovarian Cancer Survival (KPROCS) Study Abstract Background: Ovarian cancer is Methods: This preliminary analysis in.......
- Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in ... relevant advance in the management of hormone receptor (HR) positive, HER2-negative metastatic breast cancer This meta-analysis of randomized controlled trials (RCTs) is aimed to better characterize the efficacy
- Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease. Therefore, it is important to identify novel genes that mediate metastasis in HER2+ breast cancer.
- A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with ... EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer receptor-tyrosine kinase inhibitors (EGFR-TKIs) against EGFR mutation-positive non-small cell lung cancer
- Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists ... Gonadotropin-releasing hormone (GnRH) antagonists and agonists are cornerstone treatments in prostate cancer The objective of this study was to systematically assess the risk of adverse cardiovascular events of
- 2023, Yongpyung Ski Camp with All Family Members Nobody knows when it will be stopped but we can enjoy this yearly event till we can. still cannot believe that he left as fast as we expected even though he was suffering from liver cancer
- 오늘의 단어 Insure, Ensure 그리고 Guarantee 보험에 가입하다, This pottery is insured for 2 million. She have insured herself against breast cancer. 유방암에 대비한 보험을 들었다.